

Yanzhi Song

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6465403/publications.pdf>

Version: 2024-02-01

60
papers

1,410
citations

304743

22
h-index

377865

34
g-index

60
all docs

60
docs citations

60
times ranked

1655
citing authors

#	ARTICLE	IF	CITATIONS
1	Phyto-phospholipid complexes (phytosomes): A novel strategy to improve the bioavailability of active constituents. <i>Asian Journal of Pharmaceutical Sciences</i> , 2019, 14, 265-274.	9.1	149
2	Correlation between mouse age and human age in anti-tumor research: Significance and method establishment. <i>Life Sciences</i> , 2020, 242, 117242.	4.3	98
3	Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. <i>International Journal of Pharmaceutics</i> , 2017, 523, 203-216.	5.2	81
4	Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2019, 92, 184-195.	8.3	69
5	The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid- ω -octadecylamine conjugate. <i>Biomaterials</i> , 2014, 35, 5216-5225.	11.4	56
6	Are PEGylated liposomes better than conventional liposomes? A special case for vincristine. <i>Drug Delivery</i> , 2016, 23, 1092-1100.	5.7	51
7	Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system. <i>International Journal of Nanomedicine</i> , 2014, 9, 2307.	6.7	47
8	Neutrophil-Mediated Delivery of Dexamethasone Palmitate-Loaded Liposomes Decorated with a Sialic Acid Conjugate for Rheumatoid Arthritis Treatment. <i>Pharmaceutical Research</i> , 2019, 36, 97.	3.5	42
9	Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity. <i>International Journal of Pharmaceutics</i> , 2018, 547, 315-329.	5.7	37
10	Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy. <i>Journal of Controlled Release</i> , 2021, 337, 393-406.	9.9	34
11	Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid- ω -octadecylamine conjugate. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 177-183.	4.0	32
12	A novel nanosuspension of andrographolide: Preparation, characterization and passive liver target evaluation in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 13-22.	4.0	32
13	Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 590, 119929.	5.2	31
14	Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2019, 571, 118706.	5.2	30
15	Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs. <i>International Journal of Nanomedicine</i> , 2015, 10, 3533.	6.7	28
16	Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy. <i>Acta Biomaterialia</i> , 2021, 134, 702-715.	8.3	28
17	Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity. <i>International Journal of Pharmaceutics</i> , 2018, 547, 315-329.	5.2	27
18	Photodynamic/ photothermal therapy enhances neutrophil-mediated ibrutinib tumor delivery for potent tumor immunotherapy: More than one plus one?. <i>Biomaterials</i> , 2021, 269, 120652.	11.4	27

#	ARTICLE	IF	CITATIONS
19	Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. <i>International Journal of Pharmaceutics</i> , 2016, 515, 449-459.	5.2	25
20	Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy. <i>Biomaterials</i> , 2022, 283, 121415.	11.4	25
21	The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH ₄ EDTA gradient. <i>International Journal of Nanomedicine</i> , 2014, 9, 3611.	6.7	24
22	Accelerated Blood Clearance of Nanoemulsions Modified with PEG-Cholesterol and PEG-Phospholipid Derivatives in Rats: The Effect of PEG-Lipid Linkages and PEG Molecular Weights. <i>Molecular Pharmaceutics</i> , 2020, 17, 1059-1070.	4.6	24
23	Evaluation of the antitumor effects of vitamin K ₂ (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1-11.	5.8	23
24	Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy. <i>AAPS PharmSciTech</i> , 2019, 20, 188.	3.3	23
25	Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes To Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon. <i>Molecular Pharmaceutics</i> , 2018, 15, 2548-2558.	4.6	20
26	Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency. <i>Drug Delivery and Translational Research</i> , 2018, 8, 602-616.	5.8	19
27	Redox- and pH-Sensitive Glycan (Polysialic Acid) Derivatives and F127 Mixed Micelles for Tumor-Targeted Drug Delivery. <i>Molecular Pharmaceutics</i> , 2018, 15, 5534-5545.	4.6	19
28	Sialic acid-conjugate modified doxorubicin nanoplatfrom for treating neutrophil-related inflammation. <i>Journal of Controlled Release</i> , 2021, 337, 612-627.	9.9	19
29	Novel Self-Assembled Ibrutinib-Phospholipid Complex for Potently Peroral Delivery of Poorly Soluble Drugs with pH-Dependent Solubility. <i>AAPS PharmSciTech</i> , 2018, 19, 3571-3583.	3.3	18
30	Exhausting tumor associated macrophages with sialic acid-polyethyleneimine-cholesterol modified liposomal doxorubicin for enhancing sarcoma chemotherapy. <i>International Journal of Pharmaceutics</i> , 2019, 558, 187-200.	5.2	17
31	Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon. <i>Drug Delivery and Translational Research</i> , 2019, 9, 66-75.	5.8	15
32	Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120552.	5.2	15
33	Development of a nattokinase-polysialic acid complex for advanced tumor treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 145, 105241.	4.0	14
34	A preliminary study of the innate immune memory of Kupffer cells induced by PEGylated nanoemulsions. <i>Journal of Controlled Release</i> , 2022, 343, 657-671.	9.9	14
35	Polysialic acid and pluronic F127 mixed polymeric micelles of docetaxel as new approach for enhanced antitumor efficacy. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 1827-1835.	2.0	13
36	Enhanced Opsonization-Independent Phagocytosis and High Response Ability to Opsonized Antigen-Antibody Complexes: A New Role of Kupffer Cells in the Accelerated Blood Clearance Phenomenon upon Repeated Injection of PEGylated Emulsions. <i>Molecular Pharmaceutics</i> , 2018, 15, 3755-3766.	4.6	13

#	ARTICLE	IF	CITATIONS
37	Sialic Acid Conjugate-Modified Liposomal Dexamethasone Palmitate Targeting Neutrophils for Rheumatoid Arthritis Therapy: Influence of Particle Size. <i>AAPS PharmSciTech</i> , 2021, 22, 16.	3.3	13
38	Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration. <i>AAPS PharmSciTech</i> , 2018, 19, 3210-3218.	3.3	12
39	The effect of monosialylganglioside mix modifying the PEGylated liposomal epirubicin on the accelerated blood clearance phenomenon. <i>Asian Journal of Pharmaceutical Sciences</i> , 2017, 12, 134-142.	9.1	11
40	Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, <i>in vitro</i> , and <i>in vivo</i> characterization. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 2016-2025.	2.0	10
41	The 12-3-12 cationic gemini surfactant as a novel gastrointestinal bioadhesive material for improving the oral bioavailability of coenzyme Q10 naked nanocrystals. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 2044-2054.	2.0	9
42	Preparation and toxicity evaluation of a novel nattokinase-tauroursodeoxycholate complex. <i>Asian Journal of Pharmaceutical Sciences</i> , 2018, 13, 173-182.	9.1	9
43	Murine RAW264.7 cells as cellular drug delivery carriers for tumor therapy: a good idea?. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 361-374.	2.3	9
44	The Contribution of PEG Molecular Weights in PEGylated Emulsions to the Various Phases in the Accelerated Blood Clearance (ABC) Phenomenon in Rats. <i>AAPS PharmSciTech</i> , 2020, 21, 300.	3.3	9
45	Neutrophils as emerging immunotherapeutic targets: Indirect treatment of tumors by regulating the tumor immune environment based on a sialic acid derivative-modified nanocomplex platform. <i>International Journal of Pharmaceutics</i> , 2022, 620, 121684.	5.2	9
46	Mixed PEGylated surfactant modifying system decrease the accelerated blood clearance phenomenon of nanoemulsions in rats. <i>Asian Journal of Pharmaceutical Sciences</i> , 2017, 12, 28-36.	9.1	8
47	A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors. <i>Pharmaceutical Research</i> , 2019, 36, 176.	3.5	8
48	The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models. <i>Pharmaceutics</i> , 2022, 14, 545.	4.5	8
49	The antitumor efficacy of docetaxel is enhanced by encapsulation in novel amphiphilic polymer cholesterol-coupled tocopheryl polyethylene glycol 1000 succinate micelles. <i>Drug Delivery and Translational Research</i> , 2017, 7, 642-653.	5.8	7
50	Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions. <i>International Journal of Pharmaceutics</i> , 2022, 612, 121365.	5.2	7
51	Comparison among different "revealers" in the study of accelerated blood clearance phenomenon. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 210-216.	4.0	6
52	Effects of Uncleavable and Cleavable PEG-Lipids with Different Molecular Weights on Accelerated Blood Clearance of PEGylated Emulsions in Beagle Dogs. <i>AAPS PharmSciTech</i> , 2020, 21, 106.	3.3	6
53	Polysialic Acid Modified Liposomes for Improving Pharmacokinetics and Overcoming Accelerated Blood Clearance Phenomenon. <i>Coatings</i> , 2020, 10, 834.	2.6	5
54	Evaluation of the Antitumor Effect and Immune Response of Micelles Modified with a Polysialic Acid-d- α -Tocopheryl Polyethylene Glycol 1000 Succinate Conjugate. <i>AAPS PharmSciTech</i> , 2021, 22, 223.	3.3	5

#	ARTICLE	IF	CITATIONS
55	A new application of monosialotetrahexosylganglioside in pharmaceuticals: preparation of freeze-thaw-resistant coenzyme Q10 emulsions. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105701.	4.0	4
56	Polysialic Acid Self-assembled Nanocomplexes for Neutrophil-Based Immunotherapy to Suppress Lung Metastasis of Breast Cancer. <i>AAPS PharmSciTech</i> , 2022, 23, 109.	3.3	4
57	Sialic acid-mediated photochemotherapy enhances infiltration of CD8+ T cells from tumor-draining lymph nodes into tumors of immunosenescent mice. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 425-439.	12.0	4
58	Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives. <i>Drug Delivery and Translational Research</i> , 2022, 12, 647-661.	5.8	3
59	Discovery in polyethylene glycol immunogenicity: The characteristic of intergenerational inheritance of anti-polyethylene glycol IgG. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 172, 89-100.	4.3	3
60	Influence of Dose on Neutrophil-Mediated Delivery of Nanoparticles for Tumor-Targeting Therapy Strategies. <i>AAPS PharmSciTech</i> , 2021, 22, 89.	3.3	2